HRP20161295T1 - Primjena antitumorskog sredstva - Google Patents
Primjena antitumorskog sredstva Download PDFInfo
- Publication number
- HRP20161295T1 HRP20161295T1 HRP20161295TT HRP20161295T HRP20161295T1 HR P20161295 T1 HRP20161295 T1 HR P20161295T1 HR P20161295T T HRP20161295T T HR P20161295TT HR P20161295 T HRP20161295 T HR P20161295T HR P20161295 T1 HRP20161295 T1 HR P20161295T1
- Authority
- HR
- Croatia
- Prior art keywords
- day
- pharmaceutical product
- use according
- treatment
- days
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612429P | 2012-03-19 | 2012-03-19 | |
| EP13711004.5A EP2827858B1 (en) | 2012-03-19 | 2013-03-15 | Administration of an antitumor agent |
| PCT/EP2013/055324 WO2013139687A1 (en) | 2012-03-19 | 2013-03-15 | Method for administration of an anti tumor agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161295T1 true HRP20161295T1 (hr) | 2016-11-18 |
Family
ID=47913395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161295TT HRP20161295T1 (hr) | 2012-03-19 | 2013-03-15 | Primjena antitumorskog sredstva |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20130245089A1 (https=) |
| EP (1) | EP2827858B1 (https=) |
| JP (2) | JP6224690B2 (https=) |
| KR (4) | KR102438597B1 (https=) |
| CN (2) | CN104203232A (https=) |
| BR (1) | BR112014018135A8 (https=) |
| CA (1) | CA2859940C (https=) |
| CY (1) | CY1118070T1 (https=) |
| DK (1) | DK2827858T3 (https=) |
| ES (1) | ES2593066T3 (https=) |
| HK (1) | HK1204934A1 (https=) |
| HR (1) | HRP20161295T1 (https=) |
| HU (1) | HUE029933T2 (https=) |
| LT (1) | LT2827858T (https=) |
| MX (1) | MX356948B (https=) |
| PL (1) | PL2827858T3 (https=) |
| PT (1) | PT2827858T (https=) |
| RS (1) | RS55250B1 (https=) |
| RU (1) | RU2638795C2 (https=) |
| SI (1) | SI2827858T1 (https=) |
| WO (1) | WO2013139687A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014114575A1 (en) * | 2013-01-22 | 2014-07-31 | F. Hoffmann-La Roche Ag | Pharmaceutical composition with improved bioavailability |
| EP3131878A1 (en) * | 2014-04-15 | 2017-02-22 | F. Hoffmann-La Roche AG | Solid forms of a pharmaceutically active compound |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| EP3204776B1 (en) * | 2014-10-10 | 2019-09-04 | F.Hoffmann-La Roche Ag | Methods for personalizing patient cancer therapy with an mdm2 antagonist |
| SG11201808728QA (en) | 2016-04-06 | 2018-11-29 | Univ Michigan Regents | Mdm2 protein degraders |
| WO2018092020A1 (en) * | 2016-11-15 | 2018-05-24 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
| CN110461881B (zh) | 2017-03-27 | 2023-06-23 | 诺伊尓免疫生物科技株式会社 | 嵌合抗原受体 |
| JP6617208B2 (ja) | 2017-03-31 | 2019-12-11 | ノバルティス アーゲー | 血液腫瘍におけるｈｄｍ２−ｐ５３相互作用阻害剤の用量およびレジメン |
| TWI791794B (zh) | 2018-03-20 | 2023-02-11 | 瑞士商諾華公司 | 藥物組合 |
| EP3897648B1 (en) | 2018-12-20 | 2023-08-23 | Novartis AG | Extended low dose regimens for mdm2 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0713119A2 (pt) * | 2006-06-30 | 2012-04-17 | Schering Corp | piperidinas substituìdas que aumentam a atividade de p53 e os usos destas |
| PL2101759T3 (pl) * | 2006-12-14 | 2019-05-31 | Exelixis Inc | Sposoby stosowania inhibitorów MEK |
| US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
-
2013
- 2013-02-05 US US13/759,647 patent/US20130245089A1/en not_active Abandoned
- 2013-03-15 RS RS20160860A patent/RS55250B1/sr unknown
- 2013-03-15 MX MX2014010586A patent/MX356948B/es active IP Right Grant
- 2013-03-15 PL PL13711004T patent/PL2827858T3/pl unknown
- 2013-03-15 HR HRP20161295TT patent/HRP20161295T1/hr unknown
- 2013-03-15 EP EP13711004.5A patent/EP2827858B1/en active Active
- 2013-03-15 KR KR1020217003250A patent/KR102438597B1/ko active Active
- 2013-03-15 LT LTEP13711004.5T patent/LT2827858T/lt unknown
- 2013-03-15 BR BR112014018135A patent/BR112014018135A8/pt not_active Application Discontinuation
- 2013-03-15 KR KR1020197008801A patent/KR20190035957A/ko not_active Ceased
- 2013-03-15 ES ES13711004.5T patent/ES2593066T3/es active Active
- 2013-03-15 KR KR1020147026019A patent/KR20140133583A/ko not_active Ceased
- 2013-03-15 DK DK13711004.5T patent/DK2827858T3/en active
- 2013-03-15 CN CN201380015189.5A patent/CN104203232A/zh active Pending
- 2013-03-15 JP JP2015500851A patent/JP6224690B2/ja active Active
- 2013-03-15 HU HUE13711004A patent/HUE029933T2/en unknown
- 2013-03-15 RU RU2014141365A patent/RU2638795C2/ru active
- 2013-03-15 KR KR1020167019798A patent/KR20160089549A/ko not_active Ceased
- 2013-03-15 CN CN201910030832.0A patent/CN110013478A/zh active Pending
- 2013-03-15 SI SI201330310A patent/SI2827858T1/sl unknown
- 2013-03-15 HK HK15105538.1A patent/HK1204934A1/xx unknown
- 2013-03-15 WO PCT/EP2013/055324 patent/WO2013139687A1/en not_active Ceased
- 2013-03-15 PT PT137110045T patent/PT2827858T/pt unknown
- 2013-03-15 CA CA2859940A patent/CA2859940C/en active Active
-
2015
- 2015-01-14 US US14/596,747 patent/US20150126575A1/en not_active Abandoned
-
2016
- 2016-10-05 CY CY20161100996T patent/CY1118070T1/el unknown
- 2016-10-06 JP JP2016197838A patent/JP2017061461A/ja active Pending
-
2019
- 2019-07-12 US US16/510,256 patent/US20190328708A1/en not_active Abandoned
-
2020
- 2020-11-18 US US16/951,153 patent/US11738003B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161295T1 (hr) | Primjena antitumorskog sredstva | |
| UA103915C2 (ru) | Твердая лекарственная форма, которая содержит линаглиптин и ингибитор sglt2, и ее применение | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| PH12016500372A1 (en) | Pharmaceutical composition containing pyrimidine compound as active ingredient | |
| CA2894892A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| BR112015022782A2 (pt) | composto, composição farmacêutica, combinação, e, uso de um composto | |
| GEP20237479B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| MX2013011086A (es) | (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas. | |
| ZA202006377B (en) | Boronic acid derivatives and therapeutic uses thereof | |
| FI3355889T3 (fi) | Diaminopyrimidiini-p2x3- ja p2x2/3-reseptorimodulaattoreita käytettäväksi yskän hoidossa | |
| MX2016005396A (es) | Composiciones para administracion oral de acido zoledronico o compuestos relacionados para tratar enfermedades. | |
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| MX347105B (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| EP2878305A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING STAT3-MEDIATED DISEASES WITH A SALVIA PLEBEIA-R. BR.- EXTRACT OR A PART OF IT AS AN ACTIVE SUBSTANCE | |
| HRP20230523T1 (hr) | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta | |
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| ME02405B (me) | Spojevi pirazola као inhibitori sglt1 | |
| BRPI0916282B8 (pt) | uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônica | |
| MX377525B (es) | Composición farmacéutica oral de sales sulfato para comprimidos de uso dual y métodos para su uso. | |
| UY35771A (es) | Tienouracil-carboxamidas cíclicas y su uso | |
| HRP20231448T1 (hr) | Primjena delgocitiniba za liječenje kroničnog ekcema ruku | |
| WO2015044961A3 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
| PH12016501026A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |